Hematopoietic Stem-Cell Gene Therapy for Cystinosis

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Lysosomal Storage Disorders

Background:

• Cystinosis is a rare genetic disorder causing cystine accumulation in lysosomes.
• Current treatments like cysteamine delay but do not halt disease progression.

Purpose of the Study:

• To evaluate the safety and efficacy of CTNS-RD-04, an ex vivo gene therapy for cystinosis.
• To assess cystine depletion in white blood cells following treatment.

Main Methods:

• Phase 1-2, open-label study of autologous CD34+ cells genetically modified with CTNS cDNA.
• Patients received CTNS-RD-04 after oral cysteamine withdrawal.
• Primary endpoints: safety and side effects; Secondary endpoints: white-cell cystine levels.

Main Results:

• Six patients received CTNS-RD-04, with sustained hematopoietic reconstitution observed.
• Adverse events were generally mild to moderate and consistent with the regimen.
• White-cell cystine levels decreased in most patients, correlating with vector copy number.

Conclusions:

• CTNS-RD-04 gene therapy demonstrated a favorable safety profile in this small cohort.
• The therapy led to a reduction in white-cell cystine levels, indicating potential therapeutic benefit.
• Further investigation is warranted for this ex vivo gene therapy approach for cystinosis.